Fig. 1From: Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective studySurvival outcomes of the patients in the two groups. a Intracranial PFS. b Systemic PFS. c OSBack to article page